ES2523518T3 - Nuevas combinaciones farmacológicas para el tratamiento de enfermedades de las vías respiratorias - Google Patents

Nuevas combinaciones farmacológicas para el tratamiento de enfermedades de las vías respiratorias Download PDF

Info

Publication number
ES2523518T3
ES2523518T3 ES11187038.2T ES11187038T ES2523518T3 ES 2523518 T3 ES2523518 T3 ES 2523518T3 ES 11187038 T ES11187038 T ES 11187038T ES 2523518 T3 ES2523518 T3 ES 2523518T3
Authority
ES
Spain
Prior art keywords
treatment
respiratory diseases
new pharmacological
pharmacological combinations
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11187038.2T
Other languages
English (en)
Inventor
Thierry Bouyssou
Ingo Konetzki
Sabine Pestel
Andreas Schnapp
Christoph Hoenke
Philipp Lustenberger
Klaus Rudolf
Michael P. Pieper
Michel Pairet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2523518(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102004019540A external-priority patent/DE102004019540A1/de
Priority claimed from DE102004052987A external-priority patent/DE102004052987A1/de
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Application granted granted Critical
Publication of ES2523518T3 publication Critical patent/ES2523518T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Combinaciones farmacológicas que, junto a un compuesto 1 (6-hidroxi-8-{1-hidroxi-2-[2-(4-metoxi-fenil)-1,1- dimetil-etilamino]-etil}-4H-benzo[1,4]oxazin-3-ona) eventualmente en forma de los distintos isómeros ópticos, mezclas de los distintos enantiómeros o racematos, de las sales por adición de ácidos con ácidos farmacológicamente inocuos, así como, eventualmente, en forma de los solvatos y/o hidratos; como otro principio activo 2 contienen una sal de tiotropio 2a y ciclesonida 2b.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
    imagen2
ES11187038.2T 2004-04-22 2005-04-18 Nuevas combinaciones farmacológicas para el tratamiento de enfermedades de las vías respiratorias Active ES2523518T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE102004019540A DE102004019540A1 (de) 2004-04-22 2004-04-22 Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
DE102004019540 2004-04-22
DE102004052987 2004-11-03
DE102004052987A DE102004052987A1 (de) 2004-11-03 2004-11-03 Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
EP05002496 2005-02-07
EP05002496 2005-02-07

Publications (1)

Publication Number Publication Date
ES2523518T3 true ES2523518T3 (es) 2014-11-26

Family

ID=34966478

Family Applications (2)

Application Number Title Priority Date Filing Date
ES05739576T Active ES2380370T3 (es) 2004-04-22 2005-04-18 Combinaciones farmacológicas que contienen benzoxazina para el tratamiento de enfermedades de las vías respiratorias
ES11187038.2T Active ES2523518T3 (es) 2004-04-22 2005-04-18 Nuevas combinaciones farmacológicas para el tratamiento de enfermedades de las vías respiratorias

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES05739576T Active ES2380370T3 (es) 2004-04-22 2005-04-18 Combinaciones farmacológicas que contienen benzoxazina para el tratamiento de enfermedades de las vías respiratorias

Country Status (32)

Country Link
EP (2) EP2422786B1 (es)
JP (1) JP2007533683A (es)
KR (2) KR20130049840A (es)
AR (1) AR049262A1 (es)
AT (1) ATE539754T1 (es)
AU (1) AU2005235419B2 (es)
BE (1) BE2015C065I2 (es)
BR (1) BRPI0510080B8 (es)
CA (1) CA2559699C (es)
CY (3) CY1113890T1 (es)
DK (2) DK1781298T3 (es)
EA (1) EA013157B1 (es)
EC (1) ECSP066947A (es)
ES (2) ES2380370T3 (es)
FI (1) FIC20170005I1 (es)
HU (1) HUS1500058I1 (es)
IL (2) IL177685A (es)
LT (1) LTC1781298I2 (es)
LU (1) LU93066I2 (es)
MY (1) MY148945A (es)
NL (1) NL300779I2 (es)
NO (2) NO337714B1 (es)
NZ (1) NZ550797A (es)
PE (1) PE20060462A1 (es)
PL (2) PL2422786T3 (es)
PT (2) PT2422786E (es)
SG (1) SG152237A1 (es)
SI (2) SI2422786T1 (es)
TW (2) TWI372056B (es)
UY (1) UY28861A1 (es)
WO (1) WO2005102349A1 (es)
ZA (1) ZA200606624B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
US7923455B2 (en) * 2005-01-28 2011-04-12 Boehringer Ingelheim International Gmbh Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
WO2006087316A1 (en) * 2005-02-16 2006-08-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising anticholinergics and etiprednol
AU2006281449B2 (en) 2005-08-15 2013-01-31 Boehringer Ingelheim International Gmbh Method for producing betamimetics
US20070088030A1 (en) 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
US20070086957A1 (en) 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases
CA2627982C (en) * 2005-11-10 2013-09-10 Nicholas S. Bodor Soft anticholinergic esters
JP2009526817A (ja) * 2006-02-16 2009-07-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療用医薬組成物
CA2660186A1 (en) * 2006-08-07 2008-02-14 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of respiratory diseases
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
JP2010507617A (ja) * 2006-10-26 2010-03-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び消化器系障害の治療用の新規な医薬組成物
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EP2245026B1 (de) 2008-02-07 2012-08-01 Boehringer Ingelheim International GmbH Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CA2744655A1 (en) * 2008-11-27 2010-06-03 Boehringer Ingelheim International Gmbh Novel powdered crystalline medicines for inhalation
WO2014016548A2 (en) * 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
JP2015533131A (ja) * 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 咳を治療するためのベータ２−アドレナリン受容体作動薬

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
PH26882A (en) 1985-07-30 1992-11-16 Glaxo Group Ltd Devices for administering medicaments to patients
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
HUP0300832A2 (hu) 2000-04-27 2003-08-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Új, lassú hatású bétamimetikumok, eljárás előállításukra és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
DK1326862T3 (da) 2000-10-12 2004-11-22 Boehringer Ingelheim Pharma Krystallinsk monohydrat af tiotropiumbromid, fremgangsmåde til fremstilling deraf og anvendelse deraf til fremstilling af et lægemiddel
KR100971616B1 (ko) 2001-06-22 2010-07-22 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
DE10230751A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und EGFR-Kinase-Hemmern
DE10246374A1 (de) * 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10253282A1 (de) * 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung

Also Published As

Publication number Publication date
BRPI0510080B8 (pt) 2021-05-25
SG152237A1 (en) 2009-05-29
EA200601846A1 (ru) 2007-04-27
KR101287460B1 (ko) 2013-07-23
CY1113890T1 (el) 2016-07-27
PL1781298T4 (pl) 2017-07-31
NO2016022I1 (no) 2016-12-01
IL177685A (en) 2013-10-31
PT2422786E (pt) 2014-11-12
NO337714B1 (no) 2016-06-06
DK2422786T3 (da) 2014-11-17
ZA200606624B (en) 2008-01-08
LU93066I2 (fr) 2016-07-11
PE20060462A1 (es) 2006-06-19
NO20065060L (no) 2006-11-21
TWI374739B (en) 2012-10-21
UY28861A1 (es) 2005-11-30
SI1781298T1 (sl) 2012-04-30
ECSP066947A (es) 2007-01-26
CY2017014I1 (el) 2017-11-14
AU2005235419B2 (en) 2010-11-04
DK1781298T3 (da) 2012-05-07
JP2007533683A (ja) 2007-11-22
KR20130049840A (ko) 2013-05-14
SI2422786T1 (sl) 2014-12-31
BE2015C065I2 (es) 2024-08-08
IL177685A0 (en) 2006-12-31
BRPI0510080B1 (pt) 2020-08-18
NZ550797A (en) 2010-08-27
TW201231055A (en) 2012-08-01
CY1115719T1 (el) 2017-01-25
AR049262A1 (es) 2006-07-12
ES2380370T3 (es) 2012-05-11
ATE539754T1 (de) 2012-01-15
MY148945A (en) 2013-06-14
EP2422786B1 (de) 2014-08-13
AU2005235419A1 (en) 2005-11-03
EA013157B1 (ru) 2010-02-26
EP1781298B1 (de) 2012-01-04
HUS1500058I1 (hu) 2016-01-28
CA2559699A1 (en) 2005-11-03
PL1781298T3 (pl) 2012-06-29
WO2005102349A1 (de) 2005-11-03
PL2422786T3 (pl) 2015-02-27
LTC1781298I2 (lt) 2018-09-25
FIC20170005I1 (fi) 2017-01-13
NO2016022I2 (no) 2016-12-01
EP2422786A1 (de) 2012-02-29
EP1781298A1 (de) 2007-05-09
TWI372056B (en) 2012-09-11
CY2017014I2 (el) 2017-11-14
NL300779I2 (nl) 2017-11-02
IL226562A0 (en) 2013-06-27
KR20070015592A (ko) 2007-02-05
CA2559699C (en) 2012-06-19
BRPI0510080A (pt) 2007-10-16
PT1781298E (pt) 2012-02-03

Similar Documents

Publication Publication Date Title
ES2523518T3 (es) Nuevas combinaciones farmacológicas para el tratamiento de enfermedades de las vías respiratorias
ES2495965T3 (es) Uso de derivados 2,5-dihidroxibencénicos para el tratamiento de enfermedades oculares
GT200000216A (es) Oxazolidinonas sustituidas y su uso.
ES2581331T3 (es) Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
UY29633A1 (es) Derivados de oxindol
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY29199A1 (es) Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones
ECSP056020A (es) Inhibidores del factor inhibidor de la migración de los macrofagos y metodos para su identificacion
AR058163A1 (es) Medicamentos exhaltadores del deseo sexual que comprenden derivados de benzimidazolona
AR059948A1 (es) Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
ES2376043T3 (es) Derivados de indazol para el tratamiento de enfermedades inducidas por hsp90.
CL2013000488A1 (es) Co-cristales de compuestos derivados de (2r)-5-oxo-1-(bencilpiperidin-4-il)-n-(piridin-2-il)pirrolidin-2-carboxamida y un agente de formacion de co-cristales; sales de los compuestos; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias e infecciosas.
AR047922A1 (es) Nuevos derivados de pentafluorsulfanilo, su obtencion y su utilizacion como agentes farmaceuticos
AR063538A1 (es) Tratamiento de la enfermedad de parkinson
AR029412A1 (es) Forma cristalina
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
NI200900161A (es) Sales de adición de ácido, hidratos y polimorfos de la etil - amida del ácido 5 - (2,4 -dihidroxi -5- isopropil - fenil) -4- (4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas.
AR049028A1 (es) Sal solida farmaceuticamente adecuada y que no sublima del enantiomero s de mirtazapina y metodo de fabricacion
AR054442A1 (es) Formas de dosificacion, composiciones farmaceuticas y metodos para el suministro sub-tenon
AR057300A1 (es) Estirilsulfonamidas, su obtencion y uso como agentes farmaceuticos
AR026704A1 (es) Forma cristalina